Event-Driven Stocks

Dare Bioscience, Inc.

DARENasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$1.0M$9,784$2.8M$10.0M$0—
Operating income−$13.6M−$23.5M−$30.9M−$31.4M−$39.1M−$27.4M
Net income−$13.4M−$4.1M−$30.2M−$30.9M−$38.7M−$27.4M
Total assets$32.5M$22.1M$21.3M$43.8M$55.8M$7.6M
Total liabilities$29.6M$28.1M$26.3M$32.7M$17.1M$8.7M
Equity$2.8M−$6.0M−$5.0M$11.1M$38.8M−$1.2M
EPS (diluted)$-1.20$-0.48$-4.15$-0.37$-0.63$-0.91
Shares out.8.9M100.6M86.2M83.9M47.3M24.7M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−1315.5%
Net margin
−1300.7%
Return on equity
−471.4%
Return on assets
−41.3%
Return on capital (ROCE)
−154.2%
Liabilities / assets
91.2%
Debt / equity
10.42×
Book value / share
$0.32
Revenue growth (YoY)
10429.4%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-20.96distress
Accruals / assets
−10.8%clean
Piotroski F-Score
6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026791,1651.0+121.0%
Apr 30, 2026358,0821.0+110.4%
Apr 15, 2026170,1672.5-19.5%
Mar 31, 2026211,4911.6-1.3%
Mar 13, 2026214,2863.6-26.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.